PolarityTE Names Board Member David Seaburg as President of Corporate Development

SALT LAKE CITY, Jan. 29, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) announced today that David Seaburg will join the Company in the newly-created role of President of Corporate Development. PolarityTE is a commercial-stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences.

In his new role, Mr. Seaburg will shape PolarityTE's corporate development strategy, including industry and institutional investor relationships, accretive acquisitions, strategic communications and programs that support the Company's enterprise and growth plans. Mr. Seaburg will retain his seat on the Company's Board of Directors, which he has held since August 2018. 

Dr. Denver M. Lough, Chairman and Chief Executive Officer of PolarityTE, said, "David has been an incredible contributor on our Board of Directors since he joined last year. His guidance as a director, deep knowledge of healthcare issues and expertise in financial and business transactions, make David the perfect choice to lead our corporate development efforts. We are thrilled to welcome David as a full-time member of the company, and look forward to benefitting from his ongoing leadership, expertise and guidance as we pursue the development of PolarityTE."

Mr. Seaburg spent the past 25 years of his career at Cowen, a leading healthcare franchise in equities research, sales and trading and investment banking. For the past 15 years, he served as Cowen's Managing Director and Head of Sales Trading, where he cultivated and led teams operating across multiple disciplines and specialties, where he leveraged human capital to drive the organization's success. Over the course of his tenure, he interacted with thousands of healthcare investors and corporate management teams. Mr. Seaburg was also a CNBC Fast Money Contributor, where he provided regular on-air market commentary for the network.

"Since joining the Board of Directors, I have learned a great deal about the company's proprietary technology and its potential impact on the healthcare industry. Tissue regeneration has been a concept discussed for decades by myself and others within healthcare equities and banking circles. I believe PolarityTE has a game-changing technology that brings that discussion to the forefront of patient care by challenging what constitutes effective therapies and clinical standards of care, and which creates exciting corporate development opportunities," said Mr. Seaburg.

About PolarityTE®
PolarityTE is a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. Rather than manufacturing with synthetic and foreign materials within artificially engineered environments, PolarityTE manufactures with the patient's own tissue and uses the patient's own body to support the regenerative process to create the same tissue from which it was derived. From a small piece of healthy autologous tissue, the company creates an easily deployable, dynamic and self-propagating product designed to regenerate the target tissues. PolarityTE's innovative method is intended to promote and accelerate growth of the patient's tissues to undergo a form of effective regenerative healing. Learn more at www.PolarityTE.com – Welcome to the Shift®.

Forward Looking Statements
Certain statements contained in this release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. They are generally identified by words such as "believes," "may," "expects," "anticipates," "intend," "plan," "will," "would," "should" and similar expressions. Readers should not place undue reliance on such forward-looking statements, which are based upon the Company's beliefs and assumptions as of the date of this release. The Company's actual results could differ materially due to risk factors and other items described in more detail in the "Risk Factors" section of the Company's Annual Reports and other filings with the SEC (copies of which may be obtained at www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. The Company specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law. Our actual results could differ materially due to risk factors and other items described in more detail in the "Risk Factors" section of the Company's Annual Reports and other filings with the SEC (copies of which may be obtained at www.sec.gov).

POLARITYTE, the POLARITYTE logo, WHERE SELF REGENERATES SELF, and WELCOME TO THE SHIFT are trademarks or registered trademarks of PolarityTE, Inc.

CONTACTS

Investors:
Rich Haerle
VP, Investor Relations
PolarityTE, Inc.
ir@PolarityTE.com
(385) 831-5284

Hans Vitzthum
LifeSci Advisors, LLC
Hans@LifeSciAdvisors.com
(617) 535-7743

Media:
Jenna Mathis
PolarityTE, Inc.
JennaMathis@polarityTE.com
(610) 751-3985

View original content to download multimedia:http://www.prnewswire.com/news-releases/polarityte-names-board-member-david-seaburg-as-president-of-corporate-development-300786193.html

SOURCE PolarityTE, Inc.